Oncimmune
Oncimmune (USA) LLC, founded in 2006, is a leader in early cancer detection, operating as a subsidiary of Oncimmune LTD based in Nottingham, England. The company specializes in developing proprietary autoantibody assay technologies to identify over 90 percent of solid-tumor cancers, which account for 70 percent of all cancer cases, including those of the lung, breast, colorectal, prostate, stomach, pancreatic, and ovarian cancers. Under the guidance of Dr. John Robertson, the chief scientific officer, Oncimmune focuses on research and development to enhance its diagnostic capabilities. The company's laboratory in metro Kansas City is CLIA-certified, ensuring compliance with regulatory standards for laboratory testing. Oncimmune holds a portfolio of patents that supports its innovative approaches in personalized immunodiagnostics, aimed at improving cancer screening, detection, and patient care.
Protagen
Acquisition in 2019
Protagen is a precision medicine company that specializes in drug development and patient management, particularly in the fields of autoimmune diseases and immuno-oncology. The company focuses on immuno-profiling and the discovery of novel autoantibody signatures, utilizing its SeroTag® technology to identify biomarkers that address challenges in the development of cancer immunotherapies and treatments for autoimmune conditions. Protagen is recognized for its expertise in patient stratification, having created disease-specific NavigAID panels that assess individual patients' autoimmune conditions and immune statuses. This tailored approach enables the development of more targeted therapies for various autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and Sjögren’s syndrome. Additionally, Protagen's biomarker discovery platform aids in the detection of autoantibodies in patients undergoing cancer immunotherapy, which helps predict treatment responses and supports informed therapeutic decisions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.